bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S4 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S4. High NRG1 level does not affect 9F7-F11-mediated inhibition of cell signaling, whereas it reduces the effect of the ligand-competing anti-HER3 antibody H4B-121. In pancreatic cancer cells, 9F7-F11 and ch9F7-F11 inhibit in a dose-dependent manner NRG1-induced signaling more efficiently than H4B-121. BxPC3 cells were pre-stimulated with 1nM or 100nM NRG1 for 5min, before adding antibodies at various concentrations for another 25min. After cell lysis, the expression levels of phosphorylated AKT (S473) and ERK1/2 (T202/T204) were quantified by HTRF. The TR-FRET signal (665 nm/620 nm emission ratio) was measured on a Pherastar FS reader and data are shown relative to 100% phosphorylation in NRG1-stimulated cells without antibody treatment (M).
Figure S1 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S1. NRG1 is a positive-allosteric modulator for 9F7-F11/HER3 binding. Differently from H4B-121 and MAB3481, 9F7-F11 does not compete with the ligand NRG1, and 9F7-F11 binding to HER3 increases in the presence of NRG1. SNAP-Tag Lumi4TM-Tb HER3-expressing HEK cells were co-incubated with various concentrations of unlabeled NRG1 and 0.5nM d2-conjugated antibodies. After 5h30 incubation, the time-resolved fluorescence (665 nm/620 nm emission delta ratio) of the binding of d2-labeled antibodies to HER3 was measured on a Pherastar reader and normalized to 100% binding (antibody-d2 conjugates without NRG1, or NRG1-d2 conjugates without antibodies). Data were plotted using the GraphPad Prism software.
Supplementary Tables S1-S2 and Supplementary Figure S1 from Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Authors: Mazor Ronit , Zhang Jingli , Xiang Laiman , Addissie Selamawit , Awuah Prince , Beers Richard , Hassan Raffit , Pastan Ira
Published: April 2023

Table S1. Cytotoxic activity in vitro in five cell lines; Table S2. In vivo toxicity of RITs; Fig S1. Cytotoxic activity in patients cells curves
Supplementary Figure 2 from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

TRX-E-002 -1 is active against chemosensitive ovarian cancer cells and spheroid cultures obtaine from ovarian cancer stem cells. (A) TRX-E-002-1 efficacy was tested against two clones of chemosensitive CD44-/MyD88- OCCs. The IC50 was calculated to be at the nM range; (B) phase contrast images showing spheroid integrity/collapse after treatment with TRX-E-002-1.
Supplementary Figure 1 from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

TRX-E-002 is more potent than current standard of careMorphological analysis of OCSCs exposed to Cisplatin, Paclitaxel, or TRX-E-002 for 24h.
Supplementary File 3_Core Enriched Genes from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

List of core-enriched genes obtained from gene set enrichment analysis.
Supplementary Figure S6 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S6. Immunohistochemistry confirms that BRG1-BRD is expressed in the xenografted tumor cells throughout the time course analyzed.
Supplementary Figure S5 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S5. BRG1-BRD has little effect on the viability of 293T and various cancer cells in the absence of irradiation.
Supplementary File 1_Rank List from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Rank list of transcriptome of sensitive cell lines divided by resistant cell lines.
Supplementary Figure S1 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S1. A model illustrating the dominant negative activity of BRG1-BRD to inhibit ÃŽÂ³-H2AX formation and DSB repair.
Supplementary Figure Legend from Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor
Authors: Brady Samuel W. , Zhang Jian , Seok Daniel , Wang Hai , Yu Dihua
Published: April 2023

PDF - 76K, Legends for Supplementary Figures 1-9.
Supplementary Table S1 and Figure Legends from Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment
Authors: Hedrich William D. , Xiao Jingwei , Heyward Scott , Zhang Yao , Zhang Junran , Baer Maria R. , Hassan Hazem E. , Wang Hongbing
Published: April 2023

Table S1: Quantitative proportion of CHOP components. Figure legends: detailed text for Figure S1 to S3.
Supplementary Figure S2 from Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment
Authors: Hedrich William D. , Xiao Jingwei , Heyward Scott , Zhang Yao , Zhang Junran , Baer Maria R. , Hassan Hazem E. , Wang Hongbing
Published: April 2023

CHOP- and DOX-induced cytotoxicity in H9c2 cells.
Supplementary Fig. S1 from Focal Adhesion Kinase as a Potential Target in AML and MDS
Authors: Carter Bing Z. , Mak Po Yee , Wang Xiangmeng , Yang Hui , Garcia-Manero Guillermo , Mak Duncan H. , Mu Hong , Ruvolo Vivian R. , Qiu Yihua , Coombes Kevin , Zhang Nianxiang , Ragon Brittany , Weaver David T. , Pachter Jonathan A. , Kornblau Steven , Andreeff Michael
Published: April 2023

Supplementary Fig. S1. The chemical structure of VS-4718.
Supplementary Table 2 from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

Genotypes of colorectal cancer cell lines.
Supplementary Figure legends from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

Legends to supplementary Figures
Supplementary Figure 4 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 4. Induction of CYP1A1, CYP1A2 and CYP1B1 gene expression by NK150460.
Supplementary Figure 3 from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

Biomarkers of response to JQ1 in colorectal cancer cell lines.
Supplementary Figures S1-S6 from Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Authors: Smith Michele C. , Mader Mary M. , Cook James A. , Iversen Philip , Ajamie Rose , Perkins Everett , Bloem Laura , Yip Yvonne Y. , Barda David A. , Waid Philip P. , Zeckner Douglas J. , Young Debra A. , Sanchez-Felix Manuel , Donoho Gregory P. , Wacheck Volker
Published: April 2023

PDF - 564 KB, Figure S1. Duodenal compound concentration profile of multiple compounds from a gastroduodenal passage simulation model; Figure S2. Kinetics of LY3023414 inhibition of PI3Kα; Figure S3. LY3023414 inhibition of mTORC1 in a concentration-dependent manner after ex vivo treatment of PMBC or whole blood; Figure S4. Activity of LY3023414 in a tumor clonogenic assay with a panel of patient-derived tumor xenografts passaged in nude mice and then grown in soft agar; Figure S5. Mean (±SD) concentrations of LY3023414 in male mice plasma, male rat plasma, and male beagle dog plasma following single dose; Figure S6. In vivo efficacy of LY3023414 and rapamycin alone and in combination using (A) H1975 and (B) 786-O xenograft tumor models.
SUPPLEMENTARY DATA from A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo
Authors: Shih Tsung-Chieh , Liu Ruiwu , Fung Gabriel , Bhardwaj Gaurav , Ghosh Paramita M. , Lam Kit S.
Published: April 2023

The methods of OB2C library and LLS compounds synthesis
Figure S6 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S6. Activation of ATF4 is not involved in toxicity induced by SW044248.
Supplementary Video 7 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Supporting Video S7. Video S6 with MR, without CT. Horizontal PET(red)/MR(grey) projection showing dynamic, systemic (tail-vein) delivery of [18F]-1. PET is overexposed in attempts to capture drug presence at glioma. Very minor quantities of [18F]-1 are delivered to glioma. (Video of Fig.4Aiv and v)
Supplementary Video 5 from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Supporting Video S5. Video S3 with MR, without CT. Horizontal PET(red)/MR(grey) projection showing dynamic, CED delivery of [18F]-1. PET is exposed to emphasize positions of largest drug concentration (i.e. gastrointestinal clearance is not visible in this window). Major quantities of [18F]-1 are delivered to glioma. (Video of Fig.4Aii and iii)
Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Authors: Huang Xinqiang , Magnus Jill , Kaimal Vivek , Karmali Priya , Li Jian , Walls Marlena , Prudente Rene , Sung Eric , Sorourian Mehran , Lee Robin , Davis Scott , Yang Xia , Estrella Heather , Lee Edmund C. , Chau B. Nelson , Pavlicek Adam , Zabludoff Sonya
Published: April 2023

Supplementary Methods and Figure legends
Supplementary Data from A Murine Model for Quantitative, Real-Time Evaluation of Convection-Enhanced Delivery (RT-CED) Using an 18[F]-Positron Emitting, Fluorescent Derivative of Dasatinib
Authors: Wang Melinda , Kommidi Harikrishna , Tosi Umberto , Guo Hua , Zhou Zhiping , Schweitzer Melanie E. , Wu Linda Y. , Singh Ranjodh , Hou Shengqi , Law Benedict , Ting Richard , Souweidane Mark M.
Published: April 2023

Chemical synthesis, characterization, in vitro, in vivo, and ex vivo studies
Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Authors: Huang Xinqiang , Magnus Jill , Kaimal Vivek , Karmali Priya , Li Jian , Walls Marlena , Prudente Rene , Sung Eric , Sorourian Mehran , Lee Robin , Davis Scott , Yang Xia , Estrella Heather , Lee Edmund C. , Chau B. Nelson , Pavlicek Adam , Zabludoff Sonya
Published: April 2023

Expression levels of miR-17 TuD. The data are expressed as delta CT value normalized to GAPDH.
Supplementary Figure 2 from Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy
Authors: Kermer Vanessa , Hornig Nora , Harder Markus , Bondarieva Anastasiia , Kontermann Roland E. , Müller Dafne
Published: April 2023

PDF - 61KB, Functional activity of RD_IL-15_scFv_m4-1BBL.
Supplementary Table S1 from Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line
Authors: Woo Jong Kyu , Jang Jeong-Eun , Kang Ju-Hee , Seong Je Kyung , Yoon Yeo Sung , Kim Hyoung-Chin , Lee Sang-Jin , Oh Seung Hyun
Published: April 2023

Differently regulated genes in both H1299_17P and H1299_17R cells
Supplementary Table 1 from Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma
Authors: Laks Dan R. , Ta Lisa , Crisman Thomas J. , Gao Fuying , Coppola Giovanni , Radu Caius G. , Nathanson David A. , Kornblum Harley I.
Published: April 2023

Canonical Pathways Associated (P<0.05) with DI39 Sensitivity
Supplementary data, Figure 3 from Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Authors: Wang Xianhui , Wong Jason , Sevinsky Christopher J. , Kokabee Leila , Khan Faiza , Sun Yan , Conklin Douglas S.
Published: April 2023

Live cell count assay showing the EGF effects on drug-treated BT474 and SKBR3 cells(72h), complete rescue, lapatinib (Lap) with EGF treatment; no rescue lapatinib, ibrutinib(Ibr) and ibrutinib with EGF treatment.
Supplementary Figure S1: The sensitivity to trastuzumab in gastric cancer cell lines from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Authors: Ishida Michihiro , Kagawa Shunsuke , Shimoyama Kyoko , Takehara Kiyoto , Noma Kazuhiro , Tanabe Shunsuke , Shirakawa Yasuhiro , Tazawa Hiroshi , Kobayashi Hisataka , Fujiwara Toshiyoshi
Published: April 2023

Human gastric cancer cell lines MKN, MKN45 and N87 cells were seeded on 96-well plates at a density of 1ï‚'103 cells/well for 24 h. The anti-HER2 monoclonal antibody trastuzumab was added at the indicated concentrations of 0, 0.01, 0.1, 1.0, 10, 100, and 1000 Î¼g/mL. The cell viability was assessed by XTT assay after 48 h. MKN1 and MKN45 cells were resistant to trastuzumab, while the growth of N87 cells was efficiently inhibited.
Supplemental Figure 1-8 from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
Authors: Sun Kaiming , Atoyan Ruzanna , Borek Mylissa A. , Dellarocca Steven , Samson Maria Elena S. , Ma Anna W. , Xu Guang-Xin , Patterson Troy , Tuck David P. , Viner Jaye L. , Fattaey Ali , Wang Jing
Published: April 2023

Supplemental Figure S1. Protein level changes induced by CUDC-907, panobinostat, or pictilisib in MYC-altered DLBCL cell lines; Supplemental Figure S2. CUDC-907 induced changes in WSU DLCL2 cells; Supplemental Figure S3. CUDC-907 changes the mRNA expression pattern of a subset of MYC target genes; Supplemental Figure S4. CUDC-907 does not induce significant body weight loss or obvious toxicity in human DLBCL cell line-derived xenograft models or Eμ-Myc transgenic tumor mouse syngeneic models of B-cell lymphoma; Supplemental Figure S5. CUDC-907 decreases MYC protein levels in cell line-derived Burkitt lymphoma xenograft tumors; Supplemental Figure S6. Protein level changes induced by CUDC-907, panobinostat, or pictilisib in MYC-dependent NMC cell lines; Supplemental Figure S7. CUDC-907 does not induce significant body weight loss or obvious toxicity in human NMC cell line-derived xenograft models; Supplemental Figure S8. Antitumor activity of CUDC-907 in human DLBCL cell line Karpas 422-derived xenograft model.
Supplementary Figure 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Authors: Zhou Yan , Zhao Conghui , Gery Sigal , Braunstein Glenn D. , Okamoto Ryoko , Alvarez Rocio , Miles Steven A. , Doan Ngan B. , Said Jonathan W. , Gu Jiang , Phillip Koeffler H.
Published: April 2023

PDF - 3892KB, Molecular structure of Cizotinib, Tivantinib, and SU11274.
Supplementary Figure 3: Dinaciclib reduces the mRNA transcripts of Rad51, its paralogs and Brca1 in vivo from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
Authors: Alagpulinsa David A. , Ayyadevara Srinivas , Yaccoby Shmuel , Shmookler Reis Robert J.
Published: April 2023

When tumor volumes had reached the predetermined limit, as indicated in Materials and Methods, the treatments were repeated for 24 h and tumors excised and immediately preserved in RNAlater. Total RNA was extracted from the tumors and subjected to RT-qPCR as described in the Materials and Methods. Results represent the mean {plus minus} SEM of at least 3 mice from each treatment group. *, **, *** and **** indicate significance of differences from DMSO controls, at p<0.05, 0.01, 0.001 and 0.0001, respectively.
Supplementary Tables S1 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Overlap of the significantly upregulated and downregulated probes in MM cell lines
Supplementary Figure S5 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Enrichment of total histone H3 and IgG (ChIP controls)
Supplementary Figure S3 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

Treatment of KMS-11 cell line with different EZH2 inhibitors
Supplementary Figure S1 from EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Authors: Hernando Henar , Gelato Kathy A. , Lesche Ralf , Beckmann Georg , Koehr Silke , Otto Saskia , Steigemann Patrick , Stresemann Carlo
Published: April 2023

MMSET expression analysis in MM cell lines
Supplementary Figures 1 and 2 from Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Authors: Parrish Karen E. , Cen Ling , Murray James , Calligaris David , Kizilbash Sani , Mittapalli Rajendar K. , Carlson Brett L. , Schroeder Mark A. , Sludden Julieann , Boddy Alan V. , Agar Nathalie Y.R. , Curtin Nicola J. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

Supplemental Figure 1. MALDI FTICR mass spectra selected from a pixel with maximum intensity in the MS images of liver (A) and flank tumor (B) sections showing the two first isotopes of rucaparib (peaks labelled 1 and 2, respectively). (C) MALDI FTICR mass spectrum selected from a pixel located in the orthotopic tumor area in the MS images of the brain section. No peak was detected for rucaparib. Black dotted lines in each H/E stained sister section delineate the MS images displayed in the figure. Supplemental Figure 2: Efficacy of rucaparib and temozolomide in orthotopic xenograft studies. Mice with established orthotopic xenografts from GBM14, GBM43 and GBM59 were randomized and treated with placebo, rucaparib 1 mg/kg/day, Days 1-5 every 28 days Ã— 3 cycles, TMZ 50 mg/kg/day, Days 1-5 every 28 days Ã— 3 cycles, or the combination.
Supplementary Figure 2 from ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer
Authors: Ruiz de Sabando Ainara , Wang Chao , He Yuanjun , García-Barros Mónica , Kim Julie , Shroyer Kenneth R. , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

ML264 treatment decreases KLF5 expression levels in DLD-1-derived xenografts.
Supplementary Figure S4 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

Images of representative abdominal skin of mice from each group.
Supplementary Figure 5 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

RNA-Seq analysis of IMIM-PC-2 and IMIM-PC-2-R cells
Supplementary Figure 1B from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Authors: Kobayashi Yoshihisa , Azuma Koichi , Nagai Hiroki , Kim Young Hak , Togashi Yosuke , Sesumi Yuichi , Chiba Masato , Shimoji Masaki , Sato Katsuaki , Tomizawa Kenji , Takemoto Toshiki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

Growth inhibitory curves of Ba/F3 cells expressing EGFR L858R
Supplementary Figure 2 from In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Authors: Altwerger Gary , Bonazzoli Elena , Bellone Stefania , Egawa-Takata Tomomi , Menderes Gulden , Pettinella Francesca , Bianchi Anna , Riccio Francesco , Feinberg Jacqueline , Zammataro Luca , Han Chanhee , Yadav Ghanshyam , Dugan Katherine , Morneault Ashley , Ponte Jose F. , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Immunohistochemistry (IHC) showing expression of FRα uterine serous cancer (USC) cell blocks
Supplementary Data from The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Authors: Wang Xinyi , Ai Jing , Liu Hongyan , Peng Xia , Chen Hui , Chen Yi , Su Yi , Shen Aijun , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Supplementary Data. This file contains all supplementary figures and legends related to the main manuscript.
Supplementary Data from The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Authors: Wang Xinyi , Ai Jing , Liu Hongyan , Peng Xia , Chen Hui , Chen Yi , Su Yi , Shen Aijun , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Table S2. Second generation sequencing data (whole exome sequencing, including Copy Number Variation,Insert deletion, Singal Nucleotide Variation and gene fusion)
Supplementary Data from The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Authors: Wang Xinyi , Ai Jing , Liu Hongyan , Peng Xia , Chen Hui , Chen Yi , Su Yi , Shen Aijun , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

Table S3. Second generation sequencing data (RNA seqencing for cytokine expression)
Table S2 from Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy
Authors: Chen Hui , Luthra Rajyalakshmi , Routbort Mark J. , Patel Keyur P. , Cabanillas Maria E. , Broaddus Russell R. , Williams Michelle D.
Published: April 2023

Distribution of mutations in advanced thyroid carcinomas
Supplementary Figure legend from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

Figure legend of Supplementary Figure 1-4
Supplemental Figure 2 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

Swimmer Plot to show the best overall response and duration of benefit in seven bladder cancer patients from Table 1 treated with HDAC inhibition.
Video 3 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Authors: Karlin Jeremy , Allen Jasmine , Ahmad Syed F. , Hughes Gareth , Sheridan Victoria , Odedra Rajesh , Farrington Paul , Cadogan Elaine B. , Riches Lucy C. , Garcia-Trinidad Antonio , Thomason Andrew G. , Patel Bhavika , Vincent Jennifer , Lau Alan , Pike Kurt G. , Hunt Thomas A. , Sule Amrita , Valerie Nicholas C.K. , Biddlestone-Thorpe Laura , Kahn Jenna , Beckta Jason M. , Mukhopadhyay Nitai , Barlaam Bernard , Degorce Sebastien L. , Kettle Jason , Colclough Nicola , Wilson Joanne , Smith Aaron , Barrett Ian P. , Zheng Li , Zhang Tianwei , Wang Yingchun , Chen Kan , Pass Martin , Durant Stephen T. , Valerie Kristoffer
Published: April 2023

U87/shp53/Centrin2-EGFP/H2B-mCherry/shp53 cells were seeded on dishes with cover slip bottoms and irradiated (5 Gy). Time-lapse videos were recorded intermittently (every 7 min) over 16 hrs. Treatment results in 12% aberrant mitoses (see Fig. 3F).
Supplemental Figure S2 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

DAR-sensitive label-free assay method design and maximal binding determination
Supplementary Figures S1-S6 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
Authors: Theunissen Jan-Willem , Cai Allen G. , Bhatti Maryam M. , Cooper Anthony B. , Avery Andrew D. , Dorfman Ryan , Guelman Sebastian , Levashova Zoia , Migone Thi-Sau
Published: April 2023

Supplementary Fig. S1. Binding characteristics of anti-TF antibodies and coagulation properties of previously described anti-TF antibodies; Supplementary Fig. S2. Epitope binning assay of anti-TF antibodies and internalization of anti-TF antibodies; Supplementary Fig. S3. Cell killing activity of anti-TF antibodies, internalization of anti-TF conjugates, and binding characteristics of anti-TF ADCs; Supplementary Fig. S4. Additional cell killing properties of anti-TF antibodies; Supplementary Fig. S5. Anti-TF ADCs do not trigger a G2/M arrest in HUVECs; Supplementary Fig. S6. Anti-TF antibodies attenuate or inhibit FVIIa-dependent Erk phosphorylation
Figure S3 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of AIF knockdown or Mcl-1 overexpression on cell death induced by ceramide nanoliposomes.
Figure S3 from KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR
Authors: Nakatani Kaori , Yamaoka Toshimitsu , Ohba Motoi , Fujita Ken-Ichi , Arata Satoru , Kusumoto Sojiro , Taki-Takemoto Iori , Kamei Daisuke , Iwai Shinichi , Tsurutani Junji , Ohmori Tohru
Published: April 2023

Acquired increases in KRAS expression in OsiR1 and OsiR2 cells, which were sensitive to cotreatment with a MEK inhibitor and an IGF1R inhibitor.
Supplemental Figure 1&2 from A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
Authors: Song Shumei , Xie Min , Scott Ailing W. , Jin Jiankang , Ma Lang , Dong Xiaochuan , Skinner Heath D. , Johnson Randy L. , Ding Sheng , Ajani Jaffer A.
Published: April 2023

Chemical structures for novel YAP1 inhibitors
Figure S4 from Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells
Authors: Fan Ping , Abderrahman Balkees , Chai Tina S. , Yerrum Smitha , Jordan V. Craig
Published: April 2023

Regulation of E2-induced apoptosis by pioglitazone in two LTED breast cancer cells. A, MCF-7:5C cells were treated with E2 (1 nM), pioglitazone (10 µM), or a combination of them for 72 hours. Then, cells were harvested for flow cytometry. B, MCF-7:2A cells were treated with E2 (1 nM), pioglitazone (10 µM), or a combination of them for 6 days. Then, cells were harvested for flow cytometry.
Supplementary Fig 2 from Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling
Authors: Gupta Nehal , Srivastava Sanjay K.
Published: April 2023

Supplementary figure S2 shows the effect of atovaquone on markers such as HER2, β-catenin, TCF-4, TCF-1, c-Myc, C-caspase3 and C-PARP by western blotting in T47D cells and CI66 cells
Supplementary Fig 4 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

TSR-033 shows little to no binding to C1q by ELISA relative to a human IgG1 reference standard
Supplementary Fig 1 from TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Authors: Ghosh Srimoyee , Sharma Geeta , Travers Jon , Kumar Sujatha , Choi Justin , Jun H. Toni , Kehry Marilyn , Ramaswamy Sridhar , Jenkins David
Published: April 2023

Profiling of human T, myeloid and NK cells in the spleens of HuNOG-EXL mice (n=3) at day 10 post-inoculation with the A549 cell line
Movie S4 from Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth In Vivo
Authors: Liu Ke , Fang Lijing , Sun Haiyan , Pan Zhengyin , Zhang Jianchao , Chen Juntao , Shao Ximing , Wang Wei , Tan Yuanyan , Ding Zhihao , Ao Lijiao , Wu Chunlei , Liu Xiaoqi , Li Huashun , Wang Rui , Su Wu , Li Hongchang
Published: April 2023

Live imaging of mitotic progression in PIP3 treated A549 cells
Figure S1-S8 from APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Authors: Local Andrea , Zhang Hongying , Benbatoul Khalid D. , Folger Peter , Sheng Xia , Tsai Cheng-Yu , Howell Stephen B. , Rice William G.
Published: April 2023

Cell growth, gene and protein expression after APTO-253 treatment. G-quadruplex binding analysis.
Supplementary methods from HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Authors: Wong So C. , Cheng Weijun , Hamilton Holly , Nicholas Anthony L. , Wakefield Darren H. , Almeida Aaron , Blokhin Andrei V. , Carlson Jeffrey , Neal Zane C. , Subbotin Vladimir , Zhang Guofeng , Hegge Julia , Bertin Stephanie , Trubetskoy Vladimir S. , Rozema David B. , Lewis David L. , Kanner Steven B.
Published: April 2023

Methods
Supplementary Table 1 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Oligonucleotides used for CRISPR/Cas9 gene editing
Supplementary Figure 3 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Densitometric analysis of basal protein expression and phosphorylation in DU145 and PC3 cells. Western blots of 3D-grown prostate cancer cell lines were evaluated with ImageJ. Phospho-protein expression was normalized to total protein expression. Results show mean {plus minus} SD (n = 3) (See also Figure 3A).
Supplemental Figure 4 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Suppl. Figs. Figures 4A/B show additional and complete data sets to support the finding of Figure 5 that ADT leads to growth arrest and causes spheroid growth delay if combined with single dose irradiation.
Supplemental Figure 3 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Suppl. Figs. 3A-C document some basic findings in the glioblastoma cell line spheroids used in the present study such as ASS/ASL expression and 3-D growth behavior.
Supplementary Figure 1 from Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Authors: Eke Iris , Makinde Adeola Y. , Aryankalayil Molykutty J. , Sandfort Veit , Palayoor Sanjeewani T. , Rath Barbara H. , Liotta Lance , Pierobon Mariaelena , Petricoin Emanuel F. , Brown Matthew F. , Stommel Jayne M. , Ahmed Mansoor M. , Coleman C. Norman
Published: April 2023

Radiation schedule for the cell culture and xenograft experiments. Human prostate cancer cells were either plated or injected subcutaneously into the flanks of the right hind legs of athymic nude mice. After 24 h (in vitro) or tumors reached a tumor size of 5 mm x 5 mm (in vivo), tumors were irradiated with different fractionation regimens including a single dose of 10 Gy at day 5, 10 fractions of 1 Gy (2 fractions per day), or 5 fractions of 2 Gy (1 fraction per day). Unirradiated cells or tumors were used as control.
Supplemental Figure 1 from Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
Authors: Hinrichs C. Noreen , Ingargiola Mirjam , Käubler Theresa , Löck Steffen , Temme Achim , Köhn-Luque Alvaro , Deutsch Andreas , Vovk Olena , Stasyk Oleh , Kunz-Schughart Leoni A.
Published: April 2023

Set-up and operational schedule of 2-D and 3-D growth, regrowth and radioresponse assays (Suppl. Fig. 1A), and procedures of image acquisition and analysis of spheroid cell migration and invasion (Suppl. Fig.1B).
Supplementary Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma
Authors: Donson Andrew M. , Amani Vladimir , Warner Elliot A. , Griesinger Andrea M. , Witt Davis A. , Levy Jean M. Mulcahy , Hoffman Lindsey M. , Hankinson Todd C. , Handler Michael H. , Vibhakar Rajeev , Dorris Kathleen , Foreman Nicholas K.
Published: April 2023

FDA panel: Details of drug screen library of 97 FDA approved anticancer active compounds. FDA drug targets: Genes corresponding to known protein targets of compounds in FDA approved oncology drug screen library, corresponding Affymetrix probeset IDs and literature source. GSEA of axitinib Tx: Axitinib-induced enrichment and depletion of MSigDB "Hallmark" genesets in transcriptomic profiles of axitinib-treated versus untreated controls.
Figure S2 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S2 shows the specificity of anti-MET VHH pool on MET in killing cancer cells.
Figure S1 from Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Authors: Su Zhipeng , Han Yunchun , Sun Qichen , Wang Xiaoxiao , Xu Ting , Xie Wei , Huang Xing
Published: April 2023

Figure S1 shows the process for generating anti-MET VHH library.
supplementary Figures-1,2,3,4 and 5 from KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer
Authors: Wang Wenyu , Lim Keng Gat , Feng Min , Bao Yi , Lee Puay Leng , Cai Yu , Chen Yufeng , Zhang Hao , Marzese Diego , Hoon Dave S.B. , Yu Qiang
Published: April 2023

Supplemental Figure 1. KDM6B and KDM6A expression profiles in breast cancer subtypes. Supplemental Figure 2. KDM6A over-expression is not associated with poor clinical outcome. Supplemental Figure 3.KDM6B knockdown does not result in cell death in SKBR3, MDA-MB-415, BT20 and SUM159 cells. Supplemental Figure 4.IGFBP5 is a prognostic factor that predicts poor prognosis in luminal breast cancer patients. Supplemental Figure5.IGFBP5 regulated by KDM6B and its effect on cell survival.
Supplementary materials and methods from A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Authors: Iwata Tomomi Nakayama , Ishii Chiaki , Ishida Saori , Ogitani Yusuke , Wada Teiji , Agatsuma Toshinori
Published: April 2023

Supplementary materials and methods
Supplementary Figure S4 from Leelamine Is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo
Authors: Singh Krishna B. , Hahm Eun-Ryeong , Pore Subrata K. , Singh Shivendra V.
Published: April 2023

Correlation of SREBF1 (SREBP1) expression with that of key fatty acid synthesis genes in normal prostate tissue from TCGA (n=52).
Supplemental Figures S1-S7 from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Authors: Kim Minjee , Ma Daniel J. , Calligaris David , Zhang Shuangling , Feathers Ryan W. , Vaubel Rachael A. , Meaux Isabelle , Mladek Ann C. , Parrish Karen E. , Jin Fang , Barriere Cedric , Debussche Laurent , Watters James , Tian Shulan , Decker Paul A , Eckel-Passow Jeanette E. , Kitange Gaspar J. , Johnson Aaron J. , Parney Ian F. , Anastasiadis Panos Z. , Agar Nathalie Y.R. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

Fig. S1: MDM2 transcript expression. RNA extracted from flank tumor xenografts from 51 PDX models was assessed by qRT-PCR for MDM2 expression in pooled triplicate samples and compared to expression in normal brain (NB). Fig. S2: MDM2 Amplification in PDX lines. Copy-number profiles were generated from whole exome sequencing of flank xenografts. MDM2 exons are highlighted in red. GBM10, GBM12, and GBM102 show normal MDM2 copy number. GBM108 and GBM143 demonstrate high-level amplification of MDM2. Fig. S3: Apoptosis by TUNEL assay in GBM108. Established flank tumor xenografts were randomized and treated for 5 days with placebo (n=5 mice) versus 50 mg/kg SAR405838 (n=5 mice). Tumor samples were then processed for TUNEL staining. TUNEL-positive cells were quantitated in six high-powered fields (HPF) for each sample. Results are plotted as mean and standard error of the mean. * P<0.05, ** P<0.01, *** P<0.001. Fig. S4: Blood brain barrier integrity in orthotopic tumors. Near-moribund mice with orthotopic GBM108 tumors were injected with TexasRed-3 kDa dextran conjugate 10 min before euthanasia and processed for cresyl violet and fluorescent microscopy on serial histology sections. Accumulation of TR-dextran within the tumor reflects disruption of the BBB. Results presented are representative of five mice analyzed. Scale bar = 500 µm. Fig. S5: VEGFA expression in GBM108 models. Short term explant cultures from parental GBM108, GBM108-empty vector (EV), and GBM108VEGFA were processed for an ELISA to measure VEGFA levels. One-way ANOVA. * P<0.05, ** P<0.01, *** P<0.001. Fig. S6: Effects of VEGFA expression on SAR405838 sensitivity. Short-term explant cultures from GBM108-Vector and GBM108-VEGFA were treated with indicated concentrations of SAR405838 for 24 hours and then relative cell number analyzed in a CyQuant assay. Fig. S7: Spatial distribution of SAR405838 in GBM108-Vector and GBM108-VEGFA intracranial tumors by MALDI-MSI.
Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Authors: Gomes Bruno , Driessens Gregory , Bartlett Derek , Cai Danying , Cauwenberghs Sandra , Crosignani Stefano , Dalvie Deepak , Denies Sofie , Dillon Christopher P. , Fantin Valeria R. , Guo Jie , Letellier Marie-Claire , Li Wenlin , Maegley Karen , Marillier Reece , Miller Nichol , Pirson Romain , Rabolli Virginie , Ray Chad , Streiner Nicole , Torti Vince R. , Tsaparikos Konstantinos , Van den Eynde Benoit J. , Wythes Martin , Yao Li-Chin , Zheng Xianxian , Tumang Joseph , Kraus Manfred
Published: April 2023

Table S2 shows a selectivity screen of PF-06840003 in in vitro pharmacological assays.
Figure S4 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

Cell cycle specific analysis of 53BP1 accretion to DSBs after incubation with BMN673
Figure S2 from Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks
Authors: Soni Aashish , Li Fanghua , Wang You , Grabos Martha , Krieger Lisa Marie , Chaudhary Shipra , Hasan Mohammad Sharif Mortoga , Ahmed Mansoor , Coleman C. Norman , Teicher Beverly A. , Piekarz Richard L. , Wang Dian , Iliakis George E.
Published: April 2023

BMN673 inhibits parylation in both normal and tumor human cell lines
Supplementary Figures 1-3. Supplmentary Tables 1-4. Supplementary Materials and Methods. from MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer
Authors: Koutsioumpa Marina , Chen Hsiao-Wang , O'Brien Neil , Koinis Filippos , Mahurkar-Joshi Swapna , Vorvis Christina , Soroosh Artin , Luo Tong , Issakhanian Shawnt , Pantuck Allan J. , Georgoulias Vassilis , Iliopoulos Dimitrios , Slamon Dennis J. , Drakaki Alexandra
Published: April 2023

Supplementary Figure S1. PPP2R2A mRNA levels in the excised tumors from 5637 bearing mouse xenografts. Supplementary Figure S2. PPP2R2A mRNA and protein levels upon transient silencing.Supplementary Figure S3. PPP2R2A protein levels upon transient overexpression. Supplementary Table S1. Bioinformatics prediction of the top networks regulated by PPP2R2A. Supplementary Table S2. Bioinformatics prediction of the top canonical pathways regulated by PPP2R2A. Supplementary Table S3. Xcelligence Cell Index and P values of siPPP2R2RA-treated versus control BC cells. Supplementary Table S4. Xcelligence Cell Index and P values of PPP2R2A-overexpressing versus control BC cells, all treated with miR-21 mimic.
Supplementary Material and Methods from Enhanced Antitumor Efficacy of Oncolytic Adenovirus–loaded Menstrual Blood–derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells
Authors: Moreno Rafael , Fajardo Carlos Alberto , Farrera-Sal Marti , Perisé-Barrios Ana Judith , Morales-Molina Alvaro , Al-Zaher Ahmed Abdullah , García-Castro Javier , Alemany Ramon
Published: April 2023

Supplementary Material and Methods
Supplementary Figure 3 from Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor
Authors: Bhatia Shilpa , Griego Anastacia , Lennon Shelby , Oweida Ayman , Sharma Jaspreet , Rohmer Christina , Uyanga Nomin , Bukkapatnam Sanjana , Van Court Benjamin , Raben David , Young Christian , Heasley Lynn , Karam Sana D.
Published: April 2023

EphB3 knockdown does not affect cell viability but enhances cell migration in LY2 cell line.
Supplementary Figures S1-S2 from Enhanced Antitumor Efficacy of Oncolytic Adenovirus–loaded Menstrual Blood–derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells
Authors: Moreno Rafael , Fajardo Carlos Alberto , Farrera-Sal Marti , Perisé-Barrios Ana Judith , Morales-Molina Alvaro , Al-Zaher Ahmed Abdullah , García-Castro Javier , Alemany Ramon
Published: April 2023

Supplementary Figure 1. Cytokine array; Supplementary Figure 2. Effect of TLR-9 knock-down on OAd-infected MenSCs properties.